image credit- shutterstock
Singapore-based Hyphens Pharma International has granted the rights to commercialise its innovative product, Cerapro® MED Skin Barrier Cream, to Louis Widmer SA via a licensing, supply and commercialisation agreement that covers six European countries, namely Switzerland, Liechtenstein, Austria, Belgium, Luxembourg and the Netherlands.
Atopic dermatitis, a common form of eczema, affects millions across all age groups. Elevated skin pH and impaired skin barrier function are key drivers of this skin condition.
Cerapro®, with its patented formulation, lowers skin pH and helps restore the skin barrier. Approved as a CE-marked medical device under the stringent European Medical Device Regulation (MDR), Cerapro® offers a novel treatment option for patients with eczema. Lowering skin pH also supports the skin’s inherent antimicrobial defence system.
Under this collaboration, Louis Widmer, a Swiss-based international cosmetics and pharmaceuticals company renowned for high-quality dermatology products since 1960, will commercialise and promote Cerapro® to dermatologists and paediatricians in the agreed markets.
Lim See Wah, Chairman and CEO of Hyphens Pharma said, “By leveraging Louis Widmer’s strong presence and expertise in dermatology, we aim to bring Cerapro® to patients in Europe while continuing to explore new growth opportunities.”
